SCHEMBL869390

SCHEMBL869390

CC(=O)N1CCc2cc(C(=O)CBr)ccc21

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.68
KDM4E B2RXH2 4/20 0.68
HPGD P15428 3/20 0.68
RECQL P46063 1/20 0.68
NOTUM Q6P988 6/20 0.60
MAPT P10636 8/20 0.59
HSD17B10 Q99714 1/20 0.59
PKM P14618 1/20 0.57
ADRB2 P07550 1/20 0.56
GAA P10253 1/20 0.56
TSHR P16473 1/20 0.56
HTT P42858 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.53
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
TP53 P04637 1/20 0.53
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
LMNA P02545 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15058559 0.92 ALDH1A1 (0.62) ALDH1A1KDM4EHPGDRECQLNOTUM
SCHEMBL5780390 0.87 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDRECQLNOTUM
SCHEMBL870500 0.87 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDRECQLNOTUM
SCHEMBL5766977 0.86 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDRECQLNOTUM
SCHEMBL5821038 0.86 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDRECQLNOTUM
SCHEMBL4856578 0.85 ALDH1A1 (0.61) ALDH1A1KDM4EHPGDRECQLNOTUM
SCHEMBL977916 0.84 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDRECQLNOTUM
SCHEMBL7486918 0.84 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDRECQLNOTUM
SCHEMBL29446551 0.83 NOTUM (0.69) ALDH1A1KDM4EHPGDRECQLNOTUM
SCHEMBL868561 0.83 NOTUM (0.69) ALDH1A1KDM4EHPGDRECQLNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055097-A9 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY INC (US) 2026-02-26 US disclosed
US-20250145611-A1 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY, INC. 2025-05-08 US disclosed
EP-2549868-B1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2015-01-07 EP disclosed
US-8859534-B2 2-carboxamide-7-piperazinyl-benzofuran derivatives Acturum Life Science AB (SE) 2014-10-14 US disclosed
US-8859534-B2 2-carboxamide-7-piperazinyl-benzofuran derivatives Acturum Life Science AB (SE) 2014-10-14 US disclosed
US-8859534-B2 2-carboxamide-7-piperazinyl-benzofuran derivatives Acturum Life Science AB (SE) 2014-10-14 US disclosed
EP-2448934-B1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES ASTRAZENECA AB (SE) 2014-05-21 EP disclosed
US-8598156-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2013-12-03 US disclosed
US-20130296296-A1 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives Acturum Life Science AB (SE) 2013-11-07 US disclosed
US-20130296296-A1 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives Acturum Life Science AB (SE) 2013-11-07 US disclosed
WO-2011119663-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-09-29 WO disclosed
WO-2011002405-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2011-01-06 WO disclosed
WO-2011002405-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2011-01-06 WO disclosed
US-20100331341-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2010-12-30 US disclosed
US-20100331341-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2010-12-30 US disclosed
US-20100331341-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2010-12-30 US disclosed
EP-0915847-A4 SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO INC (US) 2001-01-17 EP disclosed
EP-0915847-A1 SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY Merck & Co., Inc. (US) 1999-05-19 EP disclosed
WO-1998004526-A1 SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1998-02-05 WO disclosed
US-5705515-A HAVING REDUCED SIDE EFFECTS MERCK & CO., INC. (US) 1998-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331341-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 C1R, HTR4, HTR2C ALDH1A1 931/4885KDM4E 789/4885HPGD 1159/4885
US-20130296296-A1 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives C1R, CBR1, HTR2C ALDH1A1 888/4885KDM4E 1702/4885HPGD 1075/4885
US-20260055097-A9 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 ALDH1A1 1094/4885KDM4E 1719/4885HPGD 1359/4885
US-20250145611-A1 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 ALDH1A1 1500/4885KDM4E 643/4885HPGD 2480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.